- Home
- AMBC vs KROS Comparison
AMBC vs KROS Comparison
Compare AMBC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBC
- KROS
- Stock Information
- Founded
- AMBC 1991
- KROS 2015
- Country
- AMBC United States
- KROS United States
- Employees
- AMBC N/A
- KROS N/A
- Industry
- AMBC Property-Casualty Insurers
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- AMBC Finance
- KROS Health Care
- Exchange
- AMBC Nasdaq
- KROS Nasdaq
- Market Cap
- AMBC 635.7M
- KROS 589.8M
- IPO Year
- AMBC 1991
- KROS 2020
- Fundamental
- Price
- AMBC $11.23
- KROS $12.35
- Analyst Decision
- AMBC Strong Buy
- KROS Buy
- Analyst Count
- AMBC 2
- KROS 11
- Target Price
- AMBC $17.00
- KROS $68.83
- AVG Volume (30 Days)
- AMBC 664.0K
- KROS 2.1M
- Earning Date
- AMBC 02-25-2025
- KROS 02-26-2025
- Dividend Yield
- AMBC N/A
- KROS N/A
- EPS Growth
- AMBC N/A
- KROS N/A
- EPS
- AMBC N/A
- KROS N/A
- Revenue
- AMBC $398,000,000.00
- KROS $651,000.00
- Revenue This Year
- AMBC N/A
- KROS $224.66
- Revenue Next Year
- AMBC N/A
- KROS N/A
- P/E Ratio
- AMBC N/A
- KROS N/A
- Revenue Growth
- AMBC 22.46
- KROS 8037.50
- 52 Week Low
- AMBC $10.12
- KROS $12.35
- 52 Week High
- AMBC $18.45
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- AMBC 35.29
- KROS 20.37
- Support Level
- AMBC $10.67
- KROS $12.35
- Resistance Level
- AMBC $12.84
- KROS $16.49
- Average True Range (ATR)
- AMBC 0.40
- KROS 0.84
- MACD
- AMBC -0.17
- KROS 1.01
- Stochastic Oscillator
- AMBC 25.35
- KROS 3.69
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. The business operations of the company include Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. The Company has three reportable segments namely Legacy Financial Guarantee Insurance, Specialty Property and Casualty Insurance and Insurance Distribution. Majority of revenues are earned from Legacy Financial Guarantee Insurance segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.